Format

Send to

Choose Destination
See comment in PubMed Commons below
Arch Pathol Lab Med. 2003 Sep;127(9):1121-3.

The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease.

Author information

  • 1Department of Chemistry, Oakland University, Rochester, Mich 48309-4477, USA. abull@oakland.edu

Abstract

OBJECTIVE:

Review the role and therapeutic potential of peroxisome proliferator-activated receptor (PPAR) gamma in colonic disorders.

DATA SOURCES:

Recent peer-reviewed scientific literature focusing on PPAR gamma in the colon.

STUDY SELECTION:

Research reports using animal models, cultured cell lines, and clinical material were examined for content related to the role of PPAR gamma in normal colon cell function, colon cancer, and inflammatory bowel disease. Issues concerned with potential therapeutic use were also considered.

DATA SYNTHESIS:

Key points pertaining to PPAR function and involvement in colon pathology were extracted and noted. Potential compromises to therapeutic utility are identified.

CONCLUSIONS:

The emerging important role of PPAR gamma in normal tissue homeostasis and pathologic outcomes suggests this receptor is a good candidate as a drug target. Several potential problems with this approach will require further investigation prior to widespread recommendations for modulation of PPAR as an efficacious therapy for cancer, chemoprevention of colon cancer, or treatment of inflammatory bowel disease. The widespread use of PPAR gamma ligands for management of type 2 diabetes (such as the glitazone class of drugs including rosiglitazone and pioglitazone) may provide a fortuitous assessment of the efficacy of long-term PPAR modulation.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Allen Press, Inc.
    Loading ...
    Write to the Help Desk